CN110652525A - 甘露糖醛二酸的组合物在治疗炎症中的应用 - Google Patents
甘露糖醛二酸的组合物在治疗炎症中的应用 Download PDFInfo
- Publication number
- CN110652525A CN110652525A CN201810721276.7A CN201810721276A CN110652525A CN 110652525 A CN110652525 A CN 110652525A CN 201810721276 A CN201810721276 A CN 201810721276A CN 110652525 A CN110652525 A CN 110652525A
- Authority
- CN
- China
- Prior art keywords
- composition
- sum
- mannuronic acid
- weight
- weights
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 35
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 35
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 title claims description 49
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 title claims description 48
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 86
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 81
- 239000002253 acid Substances 0.000 claims description 45
- 238000006116 polymerization reaction Methods 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 24
- 150000004043 trisaccharides Chemical class 0.000 claims description 23
- 150000002016 disaccharides Chemical class 0.000 claims description 19
- 150000007513 acids Chemical class 0.000 claims description 15
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 claims description 11
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 11
- GSCHIGXDTVYEEM-UHFFFAOYSA-N 2-[2-[[3-[6-[[4,5-dihydroxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(OCC2C(C(O)C(O)C(OC3C(OC(O)C(O)C3O)CO)O2)OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)OC3C(C(O)C(O)C(CO)O3)O)O2)O)OCC(O)C1O GSCHIGXDTVYEEM-UHFFFAOYSA-N 0.000 claims description 10
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000003959 neuroinflammation Effects 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000000047 product Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 235000000346 sugar Nutrition 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 235000010443 alginic acid Nutrition 0.000 description 16
- 229920000615 alginic acid Polymers 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 206010015150 Erythema Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000000569 multi-angle light scattering Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 150000002402 hexoses Chemical class 0.000 description 7
- -1 mannuronic acid oligosaccharide Chemical class 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Chemical class 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012505 Superdex™ Substances 0.000 description 6
- 239000000783 alginic acid Substances 0.000 description 6
- 229960001126 alginic acid Drugs 0.000 description 6
- 150000004781 alginic acids Chemical class 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 210000001872 metatarsal bone Anatomy 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 229920003045 dextran sodium sulfate Polymers 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000010525 oxidative degradation reaction Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 229920000985 (beta-D-Mannuronate)n Polymers 0.000 description 3
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical group C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical compound [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 2
- 239000005750 Copper hydroxide Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910001956 copper hydroxide Inorganic materials 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001137 tarsal bone Anatomy 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000002203 sacroiliac arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种甘露糖醛二酸寡糖组合在治疗炎症方面的应用。
Description
技术领域
本发明涉及通过生物活性筛选的方法得到甘露糖醛二酸的最佳组合物在治疗炎症方面的应用。
背景技术
炎症(Inflammation)是指生物组织受到外伤、出血或病原感染、异物等刺激,激发的生理反应。炎症反应涉及一些特定自体活性物质,如前列腺素类和白三烯类物质,及特定炎性细胞因子,如白介素类等物质的变化。炎症的发生除清除异物、消除感染外。过度的炎症反应还能够损伤机体自身物质。目前,常用抗炎药物除对因使用抗生素外,主要是甾体和非甾体抗炎药物。
甘露糖醛二酸由于其潜在的药用价值已经受到广泛的重视。甘露糖醛二酸通常以海藻酸为原料经过多步骤制得。
在原料海藻酸的多糖分子中,有由甘露糖醛酸(D-mannuronic acid)通过β-1,4-糖苷键连接形成的M段、古罗糖醛酸(L-guluronic acid)通过α-1,4-糖苷键连接形成的G段,以及由这两种糖杂合形成的MG段。甘露糖醛酸和古罗糖醛酸的结构式如下(I)式所示:
M段和G段可以从原料海藻酸中分离。通常的方法可以简单描述为:将海藻酸初步降解后可得到聚甘露糖醛酸和聚古罗糖醛酸的混合多糖,混合多糖再经酸法沉淀后,可以除去其中的聚古罗糖醛酸,进一步精制可以得到纯度在90%以上的均聚甘露糖醛酸(下文中也称“M段中间体”)。例如,可参见中国专利申请No.98806637.8以及CN02823707.2所披露的方法。
为制备寡聚甘露糖醛酸,可将上述得到的M段中间体在酸性条件下加热进一步酸解得到所需分子量范围的小片段甘露糖醛酸聚合物。另外,也有通过氧化降解的办法提升降解效率,同时可以将还原末端氧化为开环的糖二酸,详见耿美玉等人的中国专利申请200580009396.5(专利文献1)及美国专利US 8835403B2(专利文献2)。为了方便叙述,专利文献1和2在下文中统称为在先专利,它们以引证的方式全部并入本文。
在先专利披露的甘露糖醛二酸的反应过程可通过如下反应方程式(II)表示,即寡聚甘露糖醛酸多糖还原端的甘露糖醛酸C1-位醛基氧化成羧基。
在上述氧化转化过程中,常用的氧化剂有碱性硫酸铜溶液,即菲林试剂,在先专利即采用了该氧化方法,具体为:在碱性条件下,将反应底物聚甘露糖醛酸即上文的M段中间体加入硫酸铜溶液中,在沸水浴中反应15分钟至2小时。该法是以Cu2+离子为氧化剂氧化醛基,反应中产生砖红色的氧化亚铜沉淀,这个反应常用于鉴定还原性糖。
在先专利公开了甘露寡糖二酸具有抗阿尔茨海默病(Alzheimer’s disease,AD)和抗糖尿病的作用。阿尔茨海默病与II型糖尿病的发病过程与淀粉样蛋白(β-amyloid及amylin)密切相关。淀粉样蛋白聚集以后产生蛋白寡聚体,进一步聚集形成纤维。这些蛋白聚集物有细胞毒性,在细胞内诱导氧化反应损伤线粒体以及引发炎症反应等级联反应,造成大量的神经元和β细胞损伤,最终导致阿尔茨海默病与II型糖尿病的发生。甘露寡糖二酸靶向淀粉样蛋白并拮抗其诱导的级联反应,由此具有预防和治疗阿尔茨海默病与II型糖尿病的作用。
在先专利CN106344594A公开了还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗炎症方面的应用,并公开了四糖-十糖混合物在治疗炎症方面的药效活性情况。
发明内容
本发明涉及一种甘露糖醛二酸寡糖组合物在治疗炎症中的用途。本发明还涉及一种治疗炎症的方法,包括给予需要治疗的患者治疗有效量的本发明所述的甘露糖醛二酸寡糖组合物。
本发明涉及的甘露糖醛二酸寡糖组合物,包含具有式(III)的甘露糖醛二酸或其药学上可接受的盐:
其中n为选自1-9的整数,m选自0,1或2,m’选自0或1,
并且其中,
n=1-5的甘露糖醛二酸的重量总和占所述组合物总重量的60%以上;
n=1-2的甘露糖醛二酸的重量总和占所述组合物总重量的低于60%。
申请人发现,特定组合的甘露糖醛二酸组合物对于治疗炎症反应表现出有利的效果,同时,由于其源于天然产物的高安全性,有利于缓解患者的慢性或急性疼痛。
附图说明
图1是产品A中二糖、三糖和四糖的质谱图。
图2是产品A中五糖、六糖和七糖的质谱图。
图3是产品A中八糖、九糖和十糖的质谱图。
图4表示单一聚合度的甘露寡糖二酸对Aβ诱导的神经炎症的抑制作用。
图5a和5b表示本发明的寡糖组合物及六糖对小鼠类风湿性关节炎的治疗作用;图5b中横坐标的编号分别对应的样品为:i:对照组;ii:模型组;iii:产品A;iv:产品B;v:产品C;vi:产品D;vii:对比实验样品;viii:六糖。
图6a和6b表示本发明的寡糖组合物及六糖对小鼠多发性硬化症的治疗作用;图6b中横坐标附图标记同图5b。
图7a和7b表示本发明的寡糖组合物及六糖对小鼠系统性红斑狼疮的治疗作用;图7b中横坐标附图标记同图5b。
图8a和8b表示本发明的寡糖组合物及六糖对小鼠炎性肠炎的治疗作用;图8b中横坐标附图标记同图5b。
具体实施方式
下文将对本发明的各个方面进行具体说明,但本发明并不限于这些具体的实施方式。本领域技术人员可以根据下文公开内容的实质对本发明进行一些修改和调整,这些调整也属于本发明的范围。
本发明涉及一种甘露糖醛二酸寡糖组合物在治疗炎症中的用途。本发明还涉及一种治疗炎症的方法,包括给予需要治疗的患者治疗有效量的本发明所述的甘露糖醛二酸寡糖组合物。
本发明涉及的甘露糖醛二酸寡糖组合物,包含具有式(III)的甘露糖醛二酸或其药学上可接受的盐:
其中n为选自1-9的整数,m选自0,1或2,m’选自0或1,
并且其中,
n=1-5的甘露糖醛二酸的重量总和占所述组合总重量的60%以上;
n=1-2的甘露糖醛二酸的重量总和占所述组合总重量的低于60%。
根据一个优选的实施方案,本发明的甘露糖醛二酸寡糖组合中m+m’=1或2的甘露糖醛二酸的重量总和不低于所述组合总重量的50%以上,优选60%-90%,更优选70%-90%。特别地,本发明的甘露糖醛二酸寡糖组合中m+m’=1的甘露糖醛二酸的重量总和不低于所述组合总重量的10%,优选30-40%。在另一个优选实施方案中,本发明的甘露糖醛二酸寡糖组合中m+m’=2的甘露糖醛二酸的重量总和不低于所述组合总重量的10%,优选30-50%。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中n=1-5的甘露糖醛二酸寡糖的重量总和占所述组合总重量的80-95%。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中n=1-2的甘露糖醛二酸寡糖的重量总和所述组合总重量的10-50%,更优选30-50%。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中n=1-3的甘露糖醛二酸寡糖的重量总和所述组合总重量的20-70%。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中n=1-3的甘露糖醛二酸的重量总和与n=4-7的甘露糖醛二酸寡糖重量总和的比例在1.0-3.5之间,优选在1.0-3.0之间。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中各聚合度甘露糖醛二酸寡糖在所述组合中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖5-25%,六糖2-20%,七糖2-20%,八糖2-20%,九糖2-20%,十糖2-20%。特别地,组合中寡糖在所述组合中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖10-20%,六糖5-15%,七糖3-10%,八糖2-5%,九糖1-5%,十糖1-5%。更优地,组合中寡糖在所述组合中的重量百分含量为:二糖10-20%,三糖18-30%,四糖15-28%,五糖15-20%,六糖5-10%,七糖3-5%,八糖2-5%,九糖1-3%,十糖1-3%。
本发明的甘露糖醛二酸寡糖组合中,其中所述药学上可接受的盐是钠盐或钾盐。
本专利申请的发明人发现,当上述9个具有新结构的寡糖按照一定的比例进行复配,可以得到高活性的寡糖组合物,其活性比活性最好的六糖还要高;尤其是添加了一定比例二糖和三糖的组合物,其活性高于不含二糖和三糖的组合物。高活性寡糖组合物中的各寡糖比例需要按照如下的比例关系进行组合:
组合物中n=1-5的甘露糖醛二酸的重量总和占所述组合总重量的60%以上,优选80-95%。n=1-2的甘露糖醛二酸的重量总和占所述组合总重量的低于60%,优选10-50%,更优选30-50%。n=1-3的甘露糖醛二酸寡糖的重量总和所述组合总重量的20-70%。其中n=1-3的甘露糖醛二酸寡糖的重量总和与n=4-7的甘露糖醛二酸寡糖重量总和的比例在1.0-3.5之间,优选在1.0-3.0之间。
本发明所述用于治疗炎症的药物包含甘露糖醛二酸寡糖组合物,其包含具有式(III)的甘露糖醛二酸或其药学上可接受的盐,以及一种或多种药学上可接受载体。本发明所述药物可以是片剂、硬胶囊、软胶囊、肠溶胶囊、微囊剂、颗粒剂、糖浆剂、注射剂、颗粒剂、乳剂、悬浮液、溶液和用于口服或非口服给药的缓释制剂的形式。
本发明所述药学上可接受载体是指本领域技术人员熟知的药学上可接受的载体,本发明的药学上可接受载体包括但不限于:填充剂、润湿剂、黏合剂、崩解剂、润滑剂、粘合剂、助流剂、掩味剂、表面活性剂、防腐剂等。填充剂包括但不限于乳糖、微晶纤维素、淀粉、糖粉、糊精、甘露醇、硫酸钙等。润湿剂与黏合剂包括但不限于羧甲基纤维素钠、羟丙基纤维素、羟丙基甲基纤维素、明胶、蔗糖、聚乙烯吡咯烷酮等。崩解剂包括但不限于羧甲基淀粉钠、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、低取代羟丙基纤维素等。润滑剂包括但不限于硬脂酸镁、微粉硅胶、滑石粉、氢化植物油、聚乙二醇、月桂醇硫酸镁等。粘合剂包括但不限于阿拉伯胶、藻酸、羧甲基纤维素钙、羧甲基纤维素钠、葡萄糖结合剂、糊精、右旋糖、乙基纤维素、明胶、液体葡萄糖、瓜尔胶、羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、硅酸铝镁、麦芽糖糊精、甲基纤维素、聚甲基丙烯酸酯、聚乙烯吡咯烷酮、预明胶化淀粉、藻酸钠、山梨醇、淀粉、糖浆和黄蓍胶。助流剂包括但不限于胶体二氧化硅、粉状纤维素、三硅酸镁、二氧化硅和滑石粉。掩味剂包括但不限于阿斯巴坦、甜菊苷、果糖、葡萄糖、糖浆、蜂蜜、木糖醇、甘露醇、乳糖、山梨醇、麦芽糖醇、甘草甜素。表面活性剂包括但不限于吐温-80、泊洛沙姆。防腐剂包括但不限于尼泊金酯、苯甲酸钠、山梨酸钾等。
在一些实施方式中,本发明还涉及用于治疗炎症的甘露糖醛二酸寡糖组合物,包含具有式(III)的甘露糖醛二酸或其药学上可接受的盐:
其中n为选自1-9的整数,m选自0,1或2,m’选自0或1,
并且其中,
n=1-5的甘露糖醛二酸的重量总和占所述组合总重量的60%以上;
n=1-2的甘露糖醛二酸的重量总和占所述组合总重量的低于60%。
根据一个优选的实施方案,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合中m+m’=1或2的甘露糖醛二酸的重量总和不低于所述组合总重量的50%以上,优选60%-90%,更优选70%-90%。特别地,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合中m+m’=1的甘露糖醛二酸的重量总和不低于所述组合总重量的10%,优选30-40%。在另一个优选实施方案中,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物中m+m’=2的甘露糖醛二酸的重量总和不低于所述组合总重量的10%,优选30-50%。
根据一个优选实施方案,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物中n=1-5的甘露糖醛二酸寡糖的重量总和占所述组合总重量的80-95%。
根据一个优选实施方案,本发明的甘露糖醛二酸寡糖组合中n=1-2的甘露糖醛二酸寡糖的重量总和所述组合总重量的10-50%,更优选30-50%。
根据一个优选实施方案,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物中n=1-3的甘露糖醛二酸寡糖的重量总和所述组合总重量的20-70%。
根据一个优选实施方案,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物中n=1-3的甘露糖醛二酸的重量总和与n=4-7的甘露糖醛二酸寡糖重量总和的比例在1.0-3.5之间,优选在1.0-3.0之间。
根据一个优选实施方案,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物中各聚合度甘露糖醛二酸寡糖在所述组合中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖5-25%,六糖2-20%,七糖2-20%,八糖2-20%,九糖2-20%,十糖2-20%。特别地,组合中寡糖在所述组合中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖10-20%,六糖5-15%,七糖3-10%,八糖2-5%,九糖1-5%,十糖1-5%。更优地,组合中寡糖在所述组合中的重量百分含量为:二糖10-20%,三糖18-30%,四糖15-28%,五糖15-20%,六糖5-10%,七糖3-5%,八糖2-5%,九糖1-3%,十糖1-3%。
本发明所述炎症包括各种炎症,包括但不限于急性炎症、慢性炎症、血管炎症、神经炎症、中枢神经炎症(例如多发性硬化症,包括脑脊髓炎等)、外周神经炎症、关节炎(例如骨关节炎、骶髂关节炎等、牛皮癣关节炎、类风湿性关节炎、风湿性关节炎等)、强直性脊柱炎、炎症性肠病(例如克罗恩病和溃疡性结肠炎)、炎症性糖尿病性溃疡、系统性红斑狼疮、炎症性皮肤病(例如银屑病、特应性皮炎、湿疹)等。
本文使用的术语“治疗”一般是指获得需要的药理和/或生理效应。该效应根据完全或部分地预防疾病或其症状,可以是预防性的;和/或根据部分或完全稳定或治愈疾病和/或由于疾病产生的副作用,可以是治疗性的。本文使用的“治疗”涵盖了对患者疾病的任何治疗,包括:(a)预防易感染疾病或症状但还没诊断出患病的患者所发生的疾病或症状;(b)抑制疾病的症状,即阻止其发展;或(c)缓解疾病的症状,即,导致疾病或症状退化。
甘露糖醛二酸寡糖组合
本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物,其包含具有式(III)的甘露糖醛二酸或其药学上可接受的盐:
其中n为选自1-9的整数,m选自0,1或2,m’选自0或1,
并且其中,
n=1-5的甘露糖醛二酸的重量总和占所述组合总重量的60%以上;
n=1-2的甘露糖醛二酸的重量总和占所述组合总重量的低于60%。
本发明涉及的甘露糖醛二酸寡糖组合是不同聚合度的甘露糖醛二酸的混合物,其主要成分是聚合度为2至10的甘露糖醛二酸寡糖。已知在甘露糖醛二酸中,活性最高的糖为4-10糖,特别是6糖。但是,发明人研究发现,在活性最高的4-10糖基础上添加一定比例活性较低的2-3糖,同等质量的给药剂量下,生物活性不降低甚至还有提高,这可能是由于分子量较小的2-3糖虽然不能单独起效,但跟其他寡糖混合后能起到协同增效的作用。但当2-3糖的比例过高时,组合物的整体活性降低。因此,组合物中2-3糖的比例必须控制在一定的范围之内。
在实际制备过程中,氧化降解反应中会产生一定量的2-3糖,通常会因其活性低,为避免影响到产品的药效,而将从产物中分离后去除。而基于发明人的上述发现,可以不需要氧化降解产物中的2-3糖分离除去,而只需控制氧化降解反应的条件,将2-3糖的比例控制在一定的范围之内,获得的组合物活性能达到甚至优于在先申请所公开的组合物,且因不用将2-3糖作为杂质去除,产品得率理论上也显著高于在先申请所公开的产品得率,大大降低生产成本,减少废弃物的排放,在实际生产中更容易实现,更易于实现工业化大生产。
在一个示例性的实施方案中,本发明所述用于治疗炎症的甘露糖醛二酸寡糖组合物的制备方法包括如下几个步骤:
(1)甘露糖醛二酸产品的制备:
M段中间体的制备。如前文所述,本发明中采用的原料M段中间体可以通过现有技术中已知的方法制备。例如中国专利申请No.98806637.8以及CN02823707.2所披露的方法。通常的方法可以简单描述为:将海藻酸初步降解后可得到聚甘露糖醛酸和聚古罗糖醛酸的混合多糖,混合多糖再经酸法沉淀后,可以除去其中的聚古罗糖醛酸,进一步精制可以得到纯度在90%以上的均聚甘露糖醛酸,即M段中间体。
臭氧氧化降解。在室温或者加热条件下使M段中间体溶解于适量的水中,搅拌,持续通入臭氧,反应开始进行。反应pH值可以通过滴加稀盐酸或者稀NaOH溶液调节至3-13之间,优选4-10,更优选6-8。温度优选为0-70℃,更优选10-45℃。反应完成以后,停止通入臭氧,调节pH至中性。
膜分离纯化。将上述所得的反应产物配成约10%浓度的溶液,通过分子截留膜分离,去除单糖以下的降解产物,收集未透过液。所采用的分子截留膜MWCO规格为1000Da-3000Da,优选2000Da。收集液经旋转蒸发仪浓缩、真空干燥即得寡聚甘露糖醛二酸混合物。经分析发现这些产品均是以二糖-十糖的寡糖且其含量是在一定比例范围的组合物。一些组合物中寡糖比例和结构确证见实施例1-3。
(2)单一聚合度寡糖的制备
将步骤(1)所得的寡糖混合物溶解,配成约10%左右的浓度,经P6凝胶色谱柱分离,紫外检测,收集各流出组分,合并相同聚合度的组分。收集到2-10糖的9个组分,分别经G10凝胶柱层析脱盐,旋转蒸发仪浓缩,真空干燥即得。一个具体的纯化制备过程见实施例4。这些柱层析、脱盐和干燥等操作是本领域技术人员所已知的。
将这9个单一聚合度的寡糖分别用抗炎症细胞模型评价药理活性,发现六糖的活性最好。
(3)寡糖组合物的治疗活性比较
将本发明的组合物与组合物与纯化获得的六糖同时比较药理活性,结果表明本发明的寡糖组合物比单一聚合度寡糖中活性最好的六糖还要好,而包含较高比例的二糖和三糖的组合物的活性略低于六糖。不囿于任何理论,推测寡糖组合物中二、三糖的百分比含量在特定的范围内使得寡糖组合能发挥协同增效的作用,当组合物中二-六糖的比例高于60%以上,且二、三糖的比例低于60%时,组合物的整体活性较高;但二、三糖的比例超过60%时,组合物的整体活性也会降低。
动物模型及药效活性评价步骤
1、神经炎症模型-Aβ刺激小胶质细胞炎症因子分泌模型
将原代小胶质细胞接种在48孔板中,培养24小时,加入药物预处理30分钟后,加入1nM老化的Aβ1-42寡聚体刺激6小时。取处理后的小胶质细胞抽提RNA做RT-PCR来检测炎症因子IL-1β的表达,来反映Aβ刺激所引起的神经炎症反应。
2、类风湿性关节炎模型-胶原诱导的小鼠关节炎模型
取雄性DBA/1小鼠,体重19-22g,随机分组:空白对照组、模型组、给药组,每组8只。除空白对照组外,其余动物于第0天尾根部皮下注射牛二型胶原-完全弗氏佐剂(CII-CFA)乳剂10mg/kg免疫致敏,第23天,腹腔注射脂多糖(LPS)1.5mg/kg。第28天开始给药,空白对照组和模型组口服生理盐水,其余各组均给予相应药物,每天给药1次,连续给药14天。LPS注射后,每天观察小鼠发病情况。当小鼠开始发病之后(出现关节炎的临床症状),根据病变的不同程度(红肿,关节变形)按照0-4分的标准进行临床评分来反应疾病进展程度。0分为无红斑和红肿;1分为近跗骨附近或踝关节或跖骨出现红斑或轻度红肿,1个脚趾红肿;2分为踝关节和跖骨轻微红斑和肿胀,或超过两个脚趾红肿;3分为踝、腕关节和跖骨中度红斑和肿胀;4分为踝、腕关节,跖骨和脚趾全部严重红肿;每个肢体的最高评分为4分,每只动物最高评分为16分。
3、多发性硬化症模型-MOG诱导的小鼠多发性硬化症模型
取雌性C57BL/6小鼠,体重17-20g,随机选出5只作为空白对照组。其余动物于第0天背部皮下注射髓鞘少突胶质细胞糖蛋白-完全弗氏佐剂(MOG-CFA)乳剂免疫致敏,MOG10mg/kg,CFA 20mg/kg,并于第0天和第2天腹腔注射百日咳毒素,10ug/kg。并于第1天开始给药,空白对照组和模型组口服生理盐水,其余各组均给予相应药物,每天给药1次,连续给药24天。免疫后第12天左右,免疫的老鼠会出现病症,开始每天密切观察记录体重和临床评分。以0-4分表示不同程度,0分为正常表现,没有明显的疾病征兆;1分为尾巴下垂无力,后肢单侧无力;2分为尾巴下垂无力,双后肢均无力步态蹒跚;3分为单侧后肢无力麻痹瘫痪;4分为双后肢均无力麻痹瘫痪,来反应疾病进展程度。
4、系统性红斑狼疮模型-MRL/lpr红斑狼疮小鼠模型
MRL/lpr转基因小鼠,具有Faslpr基因的纯合子突变,可以自发形成淋巴组织增生,小鼠在第10-14周龄左右开始发病,出现系统性红斑狼疮症状。雌性MRL/lpr转基因小鼠,9周龄,随机分组:空白对照组、给药组,每组8只。空白对照组口服生理盐水,其余各组均给予相应药物,每天给药1次,连续给药4周。每周进行一次淋巴结评分。以0-6分表示不同程度,0分为正常;1分为在一个两侧点位置直径小于1cm;2分为在两个两侧点位置直径小于1cm;3分为在三个两侧点位置直径小于1cm;4分为在一个两侧点位置直径大于1cm,另外两个两侧点位置直径小于1cm;5分为在两个两侧点位置直径大于1cm,另外一个两侧点位置直径小于1cm;6分为在三个两侧点位置直径大于1cm。
5、炎症性肠病(IBD)模型-葡聚糖硫酸钠(dextran sulfate sodium,DSS)诱导小鼠结肠炎模型
取雌性C57小鼠,7-8周龄,体重18-20g,随机分组:空白对照组、模型组、给药组,每组8只。模型组、给药组小鼠于第1-7天以饮水方式给予2.5%的高分子量聚合物葡聚糖硫酸钠(dextran sulfate sodium,DSS)造模,并于第1天开始给药,空白对照组和模型组口服生理盐水,其余各组均给予相应药物,每天给药1次,连续给药30天。第31天,小鼠颈椎脱臼处死,打开腹腔,分离肠系膜。取每只小鼠回盲部起始端到肛门末端,每组顺次取样,计量结肠长度。
本发明的优点在以下非限制性的实施例中进一步进行说明。但实施例中采用的具体材料及其用量,以及其他实验条件并不应理解为对本发明的限制。除非特别指明,本发明中份数、比例、百分比等均以质量计。
实施例
实施例1:
步骤1):甘露糖醛二酸寡糖混合物的制备
如在先专利所披露的方法制备M段中间体,具体操作简述如下:
将5Kg海藻酸钠配成约10%的溶液,加稀盐酸调pH至3.0左右,升温至80℃,搅拌,反应10hr,停止加热,冷却至室温后,加NaOH调pH值至9.0,再加稀盐酸回调pH至2.85,离心机5000 rpm离心10min,收集上清,加HCl调pH至1.0,离心,收集沉淀,旋转蒸发仪浓缩,真空干燥得M段中间体1500g。称取500g M-段中间体,加蒸馏水溶解后,配成5L体积的溶液,NaOH调pH至6.5,水浴加热,控制反应温度到75℃。调节氧气钢瓶出口的气流量和臭氧发生器的功率,使得臭氧质量浓度流量达到8g/hr,通入反应液中。反应4hr后停止通入臭氧,加适量水调整溶液浓度至10%左右,以截留分子量为2000Da的超滤膜过滤,收集未透过液,旋转蒸发仪浓缩,真空干燥,得350g甘露糖醛二酸产品A。
步骤2):甘露糖醛二酸产品A中各聚合度寡糖的比例和结构分析
精密称取100mg上述干燥的甘露糖醛二酸产品A,加水溶解配制成10mg/mL的浓度,过0.22um滤膜,做为供试样品溶液。采用Superdex peptide(GE公司)分子排阻色谱联用多角度激光散射(MALS,怀雅特公司)测定组合物中不同聚合度寡糖的比例。实验方法如下:
色谱柱:Superdex peptide 10/300Gl
流动相:0.1mol/L NaCl
进样量:10uL
流速:0.3mL/min
测试结果:二糖-十糖分别以dp2-dp10表示,分别为dp2为19%,dp3为25%,dp4为22%,dp5为13%,dp6为9%,dp7为6%,dp8为3%,dp9为2%,dp10为1%。
步骤3):LC-MS分析甘露糖醛二酸产品A中各聚合度寡糖的结构
实验条件:
色谱柱:Superdex peptide 10/300Gl
流动相:20%甲醇+80%80mmol/L NH4Ac
流速:0.1mL/min
柱温:25℃±0.8℃。
质谱条件:Agilent 6540 QTOF;离子源:ESI碰撞电压120V;负离子模式。采集信号(m/z)宽度为100-1000。
各聚合度寡糖的质谱图见附图1-3所示。对质谱图中各信号峰进行归属,验证了产品A中所有寡糖的分子结构,即通式(III)所示的结构。信号归属及该信号所对应的结构见下表1。
由上述质谱结构解析发现,产品A中糖链还原末端的甘露糖醛酸氧化为糖二酸结构(结构见通式III),该糖二酸可以是含6个碳(m+m’=3)的甘露糖二酸结构,含量约为10%~30%,也可以是甘露糖二酸的脱羧产物,即5个碳(m+m’=2)的糖二酸(30~50%)和4个碳(m+m’=1)的糖二酸(30%~40%)。
实施例2:
称取100g实施例1中的M-段中间体,加蒸馏水溶解后,配成0.8L体积的溶液,NaOH调pH至4.0,室温25℃反应。调节氧气钢瓶出口的气流量和臭氧发生器的功率,使得臭氧质量浓度流量达到1g/hr,通入反应液中。反应10hr后停止通入臭氧,加适量水调整溶液浓度至15%左右,以截留分子量为1000Da的超滤膜过滤,收集未透过液,旋转蒸发仪浓缩,真空干燥,得80g甘露糖醛二酸产品B。
采用Superdex peptide(GE公司)分子排阻色谱联用多角度激光散射(MALS,怀雅特公司)测定B中各聚合度寡糖组分的比例。测定方法同实施例1中相关部分。测试结果:二糖-十糖分别以dp2-dp10表示,分别为dp2为20%,dp3为25%,dp4为19%,dp5为12%,
dp6为9%,dp7为5%,dp8为5%,dp9为3%,dp10为2%。
实施例3:
称取100g实施例1中的M-段中间体,加蒸馏水溶解后,配成1.5L体积的溶液,NaOH调pH至9.0,水浴45℃反应。调节氧气钢瓶出口的气流量和臭氧发生器的功率,使得臭氧质量浓度流量达到3g/hr,通入反应液中。反应2hr后停止通入臭氧,加适量水调整溶液浓度至5%左右,以截留分子量为3000Da的超滤膜过滤,收集未透过液,旋转蒸发仪浓缩,真空干燥,得60g甘露糖醛二酸产品C。
采用Superdex peptide(GE公司)分子排阻色谱联用多角度激光散射(MALS,怀雅特公司)测定C中各聚合度寡糖组分的比例。测定方法同实施例1中相关部分。测试结果:二糖-十糖分别以dp2-dp10表示,分别为dp2为8%,dp3为20%,dp4为28%,dp5为19%,dp6为13%,dp7为6%,dp8为3%,dp9为2%,dp10为1%。
实施例4:
步骤1)单一聚合度的甘露糖醛二酸寡糖的制备,方法如下:
1、样品准备:由实施例1中制备得到的甘露糖醛二酸产品A中取出300g,加水溶解,配置成1000mL的浓溶液,放置在4℃冰箱备用。每次使用时取出50mL加水稀释1倍后,用0.22um超滤膜抽滤。
2、色谱分离条件:色谱仪为AKTA pure 150(购置于GE公司),配UV检测器和自动收集器。分离色谱柱:1.2kg BioGel P6(购于伯乐公司)用去离子水混合,真空脱气以后,手动填装到玻璃柱(10cm内径)中,纯水冲洗10倍柱体积以后,色谱柱床稳定,高度为1.0m。然后改用0.02M的NaCl溶液为流动相,平衡10倍柱体积以后,开始上样。
3、上样和分离:泵的流速设置为1mL/min,将100mL的样品溶液通过色谱仪自带的泵抽到色谱柱顶端后,切换到流动相,以5mL/min的流速洗脱,待死水体积部分流出以后,开始自动收集,每管收集50mL。
4、重复上样,20次重复制备以后,合并相同组分,旋转蒸发仪浓缩,冷冻干燥,得到二糖至十糖共9个单一聚合度的寡糖。
步骤2)药理活性评价
单一聚合度的甘露寡糖二酸寡糖的药理活性评价步骤如下:
1、单一聚合度寡糖对Aβ引起的神经炎症的影响
取二糖-十糖各1mg,实验过程按照“Aβ引起的神经炎症”的方法进行。
通过测定Aβ刺激后小胶质细胞中主要功能炎症因子IL-1β的表达量,来反映药物对神经炎症的抑制作用,进行各个寡糖之间药效的对比评价。结果发现Aβ模型组与空白对照组相比,神经炎症明显增强。各单一聚合度寡糖均有减少神经炎症的趋势,其中聚合度4-10的单一聚合度甘露糖醛二酸寡糖均可明显降低IL-1β的表达量,5-8四种聚合度寡糖作用尤佳。六糖的活性最佳,2-3糖的效果较弱。见附图4。
实施例5
组合物与六糖之间的药理活性评价,考察组合物中不同聚合度寡糖之间的协同增效作用及寡糖比例范围。
样品准备:
组合物产品D:实施例4中制备得到的单一聚合度的甘露糖醛二酸寡糖,按照聚合度的大小从二糖到十糖准确称量,各糖取出的重量如下:二糖3.0g,三糖3.0g,四糖1.5g,五糖1.5g,六糖0.4g,七糖0.2g,八糖0.2g,九糖0.1g,十糖0.1g,混匀得10g组合物产品D。
对比实验样品制备
参照在先专利CN106344592A实施例1和2披露的方法制备含四糖-十糖的混合物
称取1g多聚甘露糖醛酸钠盐(重均分子量8235Da,上海绿谷制药有限公司提供),加入适量蒸馏水配成1%(重量百分比)的多聚甘露糖醛酸钠水溶液。用盐酸将所述1%的多聚甘露糖醛酸钠水溶液的pH值调节为4,然后将该水溶液置于高压釜中。在110℃温度下加热反应4小时。从高压釜中取出该反应后的溶液并使其冷却。冷却后,用NaOH溶液调节该反应后溶液的pH值得到中性液体。在搅拌条件下,将所述中性液体缓慢加入到该液体体积4倍体积量的乙醇中,进行醇沉并静置过夜。过滤分离醇沉所得固体物质,并在过滤分离时用无水乙醇洗涤过滤分离所得固体物质,最终得到白色滤饼。将该滤饼置于60℃烘箱中干燥,得褐藻胶寡糖粗品。
取5g褐藻胶寡糖粗品配成5%(重量百分比)的水溶液。通过向50ml的10%(重量百分比)氢氧化钠溶液中加入25ml的5%(重量百分比)的硫酸铜溶液并立即混匀制备得到新鲜氧化剂氢氧化铜。将该新鲜氧化剂氢氧化铜立即加入到40ml上述5%(重量百分比)的褐藻胶寡糖溶液中,同时通过沸水浴进行加热,直至不再有砖红色沉淀产生。将该反应体系进行离心处理以去除沉淀从而得到上清液。取少许上清液再次加入所述氧化剂,检查是否还有砖红色沉淀产生。若还有砖红色沉淀产生,则将上述离心所得全部上清液与另外部分的所述氧化剂继续进行反应,直至检验不再有砖红色沉淀产生为止。将最后得到的反应体系离心分离获得上清液。向上清液中加入4倍体积量的95%乙醇进行醇沉,并静置过夜。过滤分离醇沉所得固体物质,并用无水乙醇洗涤该固体物质。将所得固体物质置于60℃烘箱中烘干,得到式(II)所示褐藻胶寡糖粗品。
取上述褐藻胶寡糖粗品1g,配成10%(重量百分比)的水溶液,用95%乙醇溶液再次进行醇沉,过滤分离再次醇沉所得沉淀物并任选地用无水乙醇洗涤。分离该沉淀物并干燥,得到固体物质。将该固体物质配成5%(重量百分比)的水溶液,用3μm孔径膜过滤该水溶液并收集滤液。将该滤液在分子排阻色谱Bio-Gel-P6凝胶柱(1.6×180cm,购自Bio-Rad公司)上进行洗脱分离,作为流动相的洗脱液为0.2mol L-1NH4HCO3。依次使用多个5毫升试管从该柱色谱收集洗脱液,然后用硫酸-咔唑法检测所述各集液管中洗脱液的糖含量。根据该检测结果分别收集含有不同分子量褐藻胶寡糖组分的洗脱液。将含有不同分子量褐藻胶寡糖组分的洗脱液各自分别减压浓缩并冷冻干燥,弃去组分1,得到分别具有不同分子量的式(II)所示褐藻胶寡糖组分2-12(n分别具有0-10的值)收集并合并n=2-8的式(II)所示褐藻胶寡糖洗脱液并干燥,然后得到n=2-8的式(II)所示褐藻胶寡糖混合物(四-十糖混合物),作为对比实验样品。
采用Superdex peptide(GE公司)分子排阻色谱联用多角度激光散射(MALS,怀雅特公司)测定对比实验样品中各聚合度寡糖组分的比例。测定方法同实施例1中相关部分。测试结果:四糖-十糖分别以dp4-dp10表示,分别为dp4为10%,dp5为12%,dp6为13%,dp7为14%,dp8为15%,dp9为19%,dp10为17%。
实施例1、2、3中分别制备得到的产品A、B、C、本实施例中的产品D以及对比实验样品的寡糖比例如下表2所示。
表2甘露糖醛二酸寡糖组合物产品及对比试验样品中的寡糖百分比
以上A、B、C、D四个样品各取10g,按照“抗炎症的药效评价动物模型”所描述的方法,比较这些组合物与六糖(6T)及对比实验样品的药理活性。
1、胶原诱导的小鼠关节炎模型
实验中,模型组与正常对照组相比,出现明显的关节炎症状,踝、腕关节和跖骨中度红斑和肿胀。临床评分达到6分,说明该关节炎模型造模成功。与模型组相比,各个给药组发病程度均有不同程度的减轻。从附图5a和5b可以看出产品A、B、C使得小鼠发病时间较对比实验样品和单一聚合度的六糖明显延迟,临床评分也低于对比实验样品和单一聚合度的六糖,说明产品A、B、C的药效活性均好于对比实验样品,且好于活性最高的单一聚合度的六糖;但产品D发病时间较早,临床评分较高,反映出产品D的活性弱于六糖。说明组合物中各寡糖之间的比例很重要,添加一定比例的二糖、三糖有协同增效作用,但当二糖、三糖的比例过高时则会降低组合物的活性。
2、MOG诱导的小鼠多发性硬化症模型
实验中,模型组与正常对照组相比,大部分小鼠出现双后肢均无力麻痹瘫痪症状,模型组平均临床评分达到3分,说明该多发性硬化症模型造模成功。与模型组相比,各给药组的炎症进展均有不同程度的减轻。从附图6a和6b可以看出产品A、B、C在整个实验过程中以及终点时的临床评分均低于对比实验样品和单一聚合度的六糖;而产品D在整个实验过程中以及终点时的临床评分略高,其抗炎活性最弱。
3、MRL/lpr红斑狼疮小鼠模型
从第10周开始,转基因小鼠开始发病,出现淋巴结肿大情况,且淋巴结评分随着时间进展不断增大,说明模型组已经成功发病,且疾病进展迅速。与模型组相比,各给药组的发病进展均有不同程度的减轻。从附图7a和7b可以看出产品A、B、C使得小鼠发病时间较对比实验样品和单一聚合度的六糖明显延迟,淋巴结评分也低于对比实验样品和单一聚合度的六糖;但产品D发病时间较早,淋巴结评分较高,因此产品D的活性弱于六糖。不囿于任何理论,结合上文中其他实验的结果,推测组合物中二糖和三糖的适量存在有利于发挥各组分之间的协同效果。
4、葡聚糖硫酸钠(dextran sulfate sodium,DSS)诱导小鼠结肠炎模型
实验结束后,模型组与正常对照组相比,结肠出现由于炎症造成的明显缩短,大部分小鼠体重明显下降,近半数模型组动物后期出现死亡,说明肠部炎症非常严重。与模型组相比,各给药组的肠部炎症均有不同程度的减轻,反映在结肠长度恢复,存活率提高上。从附图8a和8b可以看出产品A、B、C使得小鼠结肠长度和动物存活率大于对比实验样品和单一聚合度的六糖;但产品D结肠长度较小,存活率也略低于六糖,反映出产品D的活性弱于六糖。同样,实验结果与前述实验一致,表明组合物中二、三糖的含量以及各组分的重量百分比对于药效的发挥有协同增效的作用,添加一定比例的二糖、三糖有协同增效作用,但当二糖、三糖的比例过高时则会降低组合物的活性。
Claims (15)
2.如权利要求1所述的用途,其中所述炎症为血管炎症、神经炎症、关节炎、强直性脊柱炎、炎症性肠病、炎症性糖尿病性溃疡、炎症性皮肤病或系统性红斑狼疮。
3.根据权利要求1所述的用途,其中所述的甘露糖醛二酸寡糖组合物中,n=1-2的甘露糖醛二酸的重量总和占所述组合物总重量的10-50%,更优选30-50%。
4.根据权利要求1所述的用途,其中所述的甘露糖醛二酸寡糖组合物中,n=1-3的甘露糖醛二酸的重量总和与n=4-7的甘露糖醛二酸重量总和的比例在1.0-3.5之间。
5.根据权利要求1所述的用途,其中所述的甘露糖醛二酸寡糖组合物中,m+m’=1或2的甘露糖醛二酸的重量总和不低于所述组合物总重量的50%以上,优选60%-90%,更优选70%-90%。
6.根据权利要求5所述的用途,其中m+m’=1的甘露糖醛二酸的重量总和不低于所述组合物总重量的10%,优选30-40%。
7.根据权利要求5所述的用途,其中m+m’=2的甘露糖醛二酸的重量总和不低于所述组合物总重量的10%,优选30-50%。
8.根据权利要求1所述的用途,其中n=1-5的甘露糖醛二酸的重量总和占所述组合物总重量的80-95%。
9.根据权利要求1所述的用途,其中n=1-3的甘露糖醛二酸的重量总和占所述组合物总重量的20-70%。
10.根据权利要求4所述的用途,其中n=1-3的甘露糖醛二酸的重量总和与n=4-7的甘露糖醛二酸重量总和的比例在1.0-3.0之间。
11.根据权利要求1-9任一项所述的用途,其中各聚合度甘露糖醛二酸在所述组合物中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖5-25%,六糖2-20%,七糖2-20%,八糖2-20%,九糖2-20%,十糖2-20%。
12.据权利要求11所述的用途,其中各聚合度甘露糖醛二酸在所述组合物中的重量百分含量为:二糖5-25%,三糖15-30%,四糖15-28%,五糖10-20%,六糖5-15%,七糖3-10%,八糖2-5%,九糖1-5%,十糖1-5%。
13.根据权利要求12所述的用途,其中各聚合度甘露糖醛二酸在所述组合物中的重量百分含量为:二糖10-20%,三糖18-30%,四糖15-28%,五糖15-20%,六糖5-10%,七糖3-5%,八糖2-5%,九糖1-3%,十糖1-3%。
14.根据权利要求1-13所述的用途,其中所述药学上可接受的盐是钠盐或钾盐。
15.一种治疗患有炎症的患者的方法,其包括给予需要的患者有效量的根据权利要求1-14任一项所述的甘露糖醛二酸寡糖组合物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810721276.7A CN110652525A (zh) | 2018-06-29 | 2018-06-29 | 甘露糖醛二酸的组合物在治疗炎症中的应用 |
PCT/CN2019/093656 WO2020001611A1 (zh) | 2018-06-29 | 2019-06-28 | 甘露糖醛二酸的组合物在治疗炎症中的应用 |
AU2019296419A AU2019296419A1 (en) | 2018-06-29 | 2019-06-28 | Use of mannuronic dicarboxylic acid composition in treatment of inflammation |
US17/256,854 US11406659B2 (en) | 2018-06-29 | 2019-06-28 | Use of mannuronic diacid composition in treatment of inflammation |
EP19825915.2A EP3815693A4 (en) | 2018-06-29 | 2019-06-28 | USE OF A DICARBOXYLIC MANNURONIC ACID COMPOSITION IN THE TREATMENT OF INFLAMMATION |
KR1020217001707A KR20210040041A (ko) | 2018-06-29 | 2019-06-28 | 염증 치료에서의 만누론 이산 조성물의 용도 |
JP2020572815A JP2021529195A (ja) | 2018-06-29 | 2019-06-28 | 炎症の治療におけるマンヌロン二酸組成物の使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810721276.7A CN110652525A (zh) | 2018-06-29 | 2018-06-29 | 甘露糖醛二酸的组合物在治疗炎症中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110652525A true CN110652525A (zh) | 2020-01-07 |
Family
ID=68985392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810721276.7A Pending CN110652525A (zh) | 2018-06-29 | 2018-06-29 | 甘露糖醛二酸的组合物在治疗炎症中的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11406659B2 (zh) |
EP (1) | EP3815693A4 (zh) |
JP (1) | JP2021529195A (zh) |
KR (1) | KR20210040041A (zh) |
CN (1) | CN110652525A (zh) |
AU (1) | AU2019296419A1 (zh) |
WO (1) | WO2020001611A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112336742A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106344594A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在治疗炎症中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1562050A (zh) * | 2004-03-24 | 2005-01-12 | 中国海洋大学 | 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用 |
WO2007069468A1 (ja) * | 2005-12-14 | 2007-06-21 | Nagasaki University | サイトカイン分泌促進剤 |
JP2016108474A (ja) * | 2014-12-08 | 2016-06-20 | 栄治 松村 | オリゴ糖の製造方法およびオリゴ糖 |
CN106344595B (zh) | 2015-07-17 | 2020-06-19 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用 |
CN106344592A (zh) | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用 |
DE102016113018A1 (de) * | 2016-07-14 | 2018-01-18 | Abbas Mirshafiey | Pharmazeutische Verwendung von beta-D-Mannuronsäure |
PL3498722T3 (pl) * | 2016-08-15 | 2021-09-20 | Shanghai Green Valley Pharmaceutical Co., Ltd. | Sposób przygotowania oligomerycznego dikwasu mannuronowego |
MY192462A (en) | 2016-12-30 | 2022-08-22 | Shanghai Inst Materia Medica Cas | Composition of mannuronic dicarboxylic acid |
-
2018
- 2018-06-29 CN CN201810721276.7A patent/CN110652525A/zh active Pending
-
2019
- 2019-06-28 KR KR1020217001707A patent/KR20210040041A/ko active Search and Examination
- 2019-06-28 US US17/256,854 patent/US11406659B2/en active Active
- 2019-06-28 AU AU2019296419A patent/AU2019296419A1/en not_active Abandoned
- 2019-06-28 WO PCT/CN2019/093656 patent/WO2020001611A1/zh active Application Filing
- 2019-06-28 JP JP2020572815A patent/JP2021529195A/ja active Pending
- 2019-06-28 EP EP19825915.2A patent/EP3815693A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106344594A (zh) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | 褐藻胶寡糖及其衍生物在治疗炎症中的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP3815693A4 (en) | 2022-04-20 |
JP2021529195A (ja) | 2021-10-28 |
AU2019296419A1 (en) | 2021-01-28 |
EP3815693A1 (en) | 2021-05-05 |
KR20210040041A (ko) | 2021-04-12 |
WO2020001611A1 (zh) | 2020-01-02 |
US20210275570A1 (en) | 2021-09-09 |
US11406659B2 (en) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102539060B1 (ko) | 만누론 이산의 조성물 | |
EP3815692A1 (en) | Composition of alginate oligosaccharide diacid | |
CN110652525A (zh) | 甘露糖醛二酸的组合物在治疗炎症中的应用 | |
WO2020001644A1 (zh) | 甘露糖醛二酸的组合物在治疗糖尿病中的应用 | |
CN110652516A (zh) | 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用 | |
US11406653B2 (en) | Use of mannuronic diacid composition in treatment of pain | |
US11406651B2 (en) | Use of mannuronic diacid composition in treatment of vascular dementia | |
WO2021023239A1 (zh) | 甘露糖醛酸寡糖治疗Th1主导相关疾病的用途 | |
CN113603808A (zh) | 改性褐藻胶及制备方法与其在制备促进胃肠蠕动药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40014915 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |